Rigel Pharmaceuticals, Inc. (RIGL)
48.67
+0.17
(+0.35%)
USD |
NASDAQ |
Sep 04, 16:00
48.65
-0.02
(-0.04%)
Pre-Market: 20:00
Rigel Pharmaceuticals Research and Development Expense (Quarterly) : 13.96M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.96M |
| March 31, 2026 | 11.68M |
| December 31, 2025 | 10.68M |
| September 30, 2025 | 7.353M |
| June 30, 2025 | 6.821M |
| March 31, 2025 | 8.436M |
| December 31, 2024 | 5.632M |
| September 30, 2024 | 6.182M |
| June 30, 2024 | 5.54M |
| March 31, 2024 | 6.026M |
| December 31, 2023 | 3.186M |
| September 30, 2023 | 6.475M |
| June 30, 2023 | 4.772M |
| March 31, 2023 | 10.09M |
| December 31, 2022 | 15.36M |
| September 30, 2022 | 14.67M |
| June 30, 2022 | 14.77M |
| March 31, 2022 | 15.47M |
| December 31, 2021 | 13.30M |
| September 30, 2021 | 18.30M |
| June 30, 2021 | 16.81M |
| March 31, 2021 | 16.83M |
| December 31, 2020 | 15.14M |
| September 30, 2020 | 14.60M |
| June 30, 2020 | 14.21M |
| Date | Value |
|---|---|
| March 31, 2020 | 16.15M |
| December 31, 2019 | 14.25M |
| September 30, 2019 | 14.46M |
| June 30, 2019 | 13.23M |
| March 31, 2019 | 10.95M |
| December 31, 2018 | 13.77M |
| September 30, 2018 | 11.10M |
| June 30, 2018 | 10.80M |
| March 31, 2018 | 11.24M |
| December 31, 2017 | 11.56M |
| September 30, 2017 | 10.81M |
| June 30, 2017 | 11.52M |
| March 31, 2017 | 12.38M |
| December 31, 2016 | 11.63M |
| September 30, 2016 | 16.17M |
| June 30, 2016 | 17.47M |
| March 31, 2016 | 18.17M |
| December 31, 2015 | 16.56M |
| September 30, 2015 | 15.50M |
| June 30, 2015 | 15.06M |
| March 31, 2015 | 15.70M |
| December 31, 2014 | 14.61M |
| September 30, 2014 | 16.15M |
| June 30, 2014 | 20.06M |
| March 31, 2014 | 16.87M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Cytokinetics, Inc. | 94.18M |
| Perspective Therapeutics, Inc. | 20.40M |
| Capricor Therapeutics, Inc. | 28.57M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |